Clinical Trial Update: A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating an anti-EGFR antibody-drug conjugate as neoadjuvant therapy for resectable locally advanced head and neck squamous cell carcinoma; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Snippet

Sponsor: West China Hospital | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING